Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd..
Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with a very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory/relapsed (R/R) disease. Nevertheless, to further optimise MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated into clinical patient management. The present review highlights recent advances in deciphering the molecular background of MCL, the definition of prognostically relevant factors and the identification of potential druggable targets and summarises current treatment recommendations for primary and R/R MCL including novel targeted therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:195 |
|---|---|
| Enthalten in: |
British journal of haematology - 195(2021), 2 vom: 01. Okt., Seite 162-173 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silkenstedt, Elisabeth [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genetics |
|---|
| Anmerkungen: |
Date Completed 16.12.2021 Date Revised 16.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17419 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323396062 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323396062 | ||
| 003 | DE-627 | ||
| 005 | 20231225184104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17419 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323396062 | ||
| 035 | |a (NLM)33783838 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silkenstedt, Elisabeth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2021 | ||
| 500 | |a Date Revised 16.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with a very limited prognosis. A better understanding of the complex biology of MCL has already led to the approval of several innovative agents, expanding the landscape of MCL therapies and improving therapeutic options especially for refractory/relapsed (R/R) disease. Nevertheless, to further optimise MCL treatment, early identification of individual risk profile and risk-adapted, patient-tailored choice of therapeutic strategy needs to be prospectively incorporated into clinical patient management. The present review highlights recent advances in deciphering the molecular background of MCL, the definition of prognostically relevant factors and the identification of potential druggable targets and summarises current treatment recommendations for primary and R/R MCL including novel targeted therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Mantle cell lymphoma | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a pathogenesis | |
| 650 | 4 | |a prognostication | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Immunoglobulin Heavy Chains |2 NLM | |
| 650 | 7 | |a SOX11 protein, human |2 NLM | |
| 650 | 7 | |a SOXC Transcription Factors |2 NLM | |
| 700 | 1 | |a Linton, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyling, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 195(2021), 2 vom: 01. Okt., Seite 162-173 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:195 |g year:2021 |g number:2 |g day:01 |g month:10 |g pages:162-173 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17419 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 195 |j 2021 |e 2 |b 01 |c 10 |h 162-173 | ||